Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06030843 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1

Study acronym: TREAT-CRS
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Nov 30, 2025 to Nov 30, 2026v5
  2. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Nov 2024 to Nov 30, 2025
    • Start date changed from estimate of Mar 2024 to Mar 1, 2025
    • Study completion date: Nov 2024 to Dec 31, 2026
    • Site details revised
  3. Start date: Nov 2023 to Mar 2024v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Effects of Empagliflozin compared with placebo in cardiorenal syndrome type 1, evaluated by MAKE30.
Trial Details
NCT Number NCT06030843
Lead Sponsor Chulalongkorn University
Conditions
(from sponsor)		 Empagliflozin in Cardiorenal Syndrome Type 1
Related terms Cardio-Renal Syndrome
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov